As April draws to a close, it's time to focus on the biotech stocks facing regulatory catalyst in the month of May. The FDA approved eight novel drugs last May, taking the total number of approvals for the year to 55. So far this year, 11 novel drugs have secured the regulatory nod. Can 2024 surpass the tally set last year? Pfizer Inc. (PFE)The FDA will decide whether or not to convert the acceler...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.